Advertisement

Journal of Assisted Reproduction and Genetics

, Volume 11, Issue 9, pp 474–477 | Cite as

Selection of ovarian stimulation protocol is related to IVF treatment outcome in women 35 years of age and older

  • György Csemiczky
  • Kerstin Hagenfeldt
  • Håkan Wramsby
Clinical Assisted Reproduction

Abstract

Purpose

The aim of this study was to assess if the woman's age influenced IVF treatment outcome when a long GnRHa-hMG or a CC-hMG ovarian stimulation protocol was used. Two hundred women were included in the study, 100 women under the age of 35 and 100 women 35 years of age and older (mean 31.8 years and 36.7 years respectively). In the younger group as well as in the older group 50 women were stimulated according to a GnRHahMG protocol and 50 women received a CC-hMG regimen.

Results

Significant differences between stimulation protocols were found in the older group for the mean numbers of oocytes recovered (4.7 vs 3.0), preembryos obtained (3.2 vs 2.0) and replaced (2.3 vs 1.7), as well as pregnancy (30 % vs 10 %) and delivery (24 % vs 4 %) rates per replacement.

Conclusion

It is concluded that women over 35 years of age seem to have a more favorable outcome of IVF treatment when using a long GnRHa-hMG protocol compared with CC-hMG, while this difference was not as obvious and lacking statistical significance under the age of 35.

Key words

in vitro fertilization age ovarian stimulation gonadotropin releasing hormone analogues clomiphene citrate human menopausal gonadotropin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Polson DW, MacLachlan V, Krapez JA, Wood C, Healy DL: A controlled study of gonadotropin-releasing hormone agonist (buserelin acetate) for folliculogenesis in routine in vitro fertilization patients. Fertil Steril 1991;56:509–514PubMedGoogle Scholar
  2. 2.
    Abdalla HI, Ahuja KK, Leonard T, Morris NN, Honour JW, Jacobs HS: Comparative trial of luteinizing hormonereleasing hormone analog/human menopausal gonadotropin and clomophene citrate/human menopausal gonadotropin in an assisted conception program. Fertil Steril 1990;53:473–478PubMedGoogle Scholar
  3. 3.
    Kubik CJ, Guzick DS, Berga SL, Zeleznik AJ: Randomizrd, prospective trial of leuprolide acetate and conventional superovulation in first cycles of in vitro fertilization and gamete intrafallopian transfer. Fertil Steril 1990;54:836–841PubMedGoogle Scholar
  4. 4.
    Sundström P, Wramsby, H: Evaluation of variations in pregnancy rates, implantation rates and early abortion rates within an in-vitro fertilization programme. Hum Reprod 1989;4:443–445PubMedGoogle Scholar
  5. 5.
    Federation CECOS, Schwartz D, Mayaux MJ: Female fecundity as a function of age: results of artificial insemination in 2193 nulliparous women with azoospermic husbands. N Engl J Med 1982;306:404–406PubMedGoogle Scholar
  6. 6.
    Meldrum DR: Female reproductive aging—ovarian and uterine factors. Fertil Steril 1993;59:1–5PubMedGoogle Scholar
  7. 7.
    Navot D, Bergh PA, Williams M, Garissi GJ, Guzman I, Sandler B, Fox J, Schreiner-Engel P, Hoffman GE, Grunfeld L: An insight into early reproductive processes through the in vivo model of ovum donation. J Clin Endocrinol Metab 1991;79: 408–414Google Scholar
  8. 8.
    Edwards RG, Fishel SB, Cohen J, Fehilly CB, Purdy JM, Slater JM, Steptoe PC, Webster JM: Factors influencing the success of in vitro fertilization for alleviating human infertility. J in Vitro Fert Embryo Transfer 1984;1:3–23Google Scholar
  9. 9.
    Piette C, de Mouzon J, Bachelot A, Spira A: In-vitro fertilization: influence of women's age on pregnancy rates. Hum Reprod 1990;5:56–59PubMedGoogle Scholar
  10. 10.
    Laufer N, Pratt BM, DeCherney AH, Naftolin F, Merino M, Markert CL: The in vivo and in vitro effects of clomiphene citrate on ovulation, fertilization, and development of cultured mouse oocytes. Am J Obstet Gynecol 1983;147:636–639Google Scholar
  11. 11.
    Macnamee MC, Howles CM, Edwards RG: Pregnancies after IVF when high tonic LH is reduced by long-term treatment with GnRH agonist. Hum Reprod 1987;2:569–571PubMedGoogle Scholar
  12. 12.
    Chetkowski RJ, Rode RA, Burruel V, Ness TE: The effect of pituitary suppression and the women's age on embryo viability and uterine receptivity. Fertil Steril 1991;56:1095–1103PubMedGoogle Scholar
  13. 13.
    Antoine JM, Salat-Baroux J, Alvarez S, Cornet D, Tibi Ch, Mandelbaum J, Plachot M: Ovarian stimulation using human menopausal gonadotropins with or without LHRH analogues in a long protocol for in vitro fertilization: a prospective randomised comparison. Hum Reprod 1990;5:565–569PubMedGoogle Scholar
  14. 14.
    Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van de Koppel P, Collins JA: The routine use of gonadotropinreleasing hormone agonist prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril 1992;58:888–896PubMedGoogle Scholar
  15. 15.
    Saunders DM, Lancaster PAL, Pedisich L: Increased pregnancy failure rates after clomiphene following assisted reproductive technology. Hum Reprod 1992;7:1154–1158PubMedGoogle Scholar
  16. 16.
    Navot D, Bergh PA, Laufer N: Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992;58:249–261PubMedGoogle Scholar
  17. 17.
    Rizk B, Smitz J: Ovarian hyperstimulation syndrome after superovulation using GnRH agonist for IVF and related procedures. Hum Reprod 1992;7:320–327PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1994

Authors and Affiliations

  • György Csemiczky
    • 1
  • Kerstin Hagenfeldt
    • 1
  • Håkan Wramsby
    • 1
  1. 1.Department of Woman and Child Health, Division for Obstetrics and GynecologyKarolinska HospitalStockholmSweden

Personalised recommendations